Stereotaxis (NYSEAMERICAN:STXS) Announces Earnings Results

Stereotaxis (NYSEAMERICAN:STXS) released its quarterly earnings data on Tuesday. The company reported ($0.05) EPS for the quarter, meeting analysts’ consensus estimates of ($0.05), FiscalAI reports. Stereotaxis had a negative net margin of 69.50% and a negative return on equity of 163.30%. The company had revenue of $7.67 million during the quarter, compared to the consensus estimate of $8.35 million.

Here are the key takeaways from Stereotaxis’ conference call:

• Recurring revenue reached $6.2 million in Q2, driven by the launch of MAGiC and a 270% sequential increase in robotic catheter revenue. Management expects recurring revenue to rise to approximately $7 million in Q3 and $8 million in Q4.
• MAGiC adoption is expanding, with roughly a dozen U.S. hospitals approved to purchase the catheter and procedure-level disposable revenue generally in the $5,000–$8,000-plus range. Demand currently exceeds supply, but the company expects about $1 million of incremental catheter revenue in each of the next two quarters as manufacturing ramps.
• Stereotaxis received its first U.S. GenesisX order and expects installation this fall alongside a non-modified X-ray, supporting formal compatibility with that manufacturer. Synchrony also generated initial orders and is expected to contribute more than $1 million of system revenue per quarter in the near term.
• Q2 revenue was $7.7 million, down year over year because no robotic system was delivered, while the company posted a $4.5 million net loss and $3.7 million of negative free cash flow. Gross margins remained pressured by low manufacturing volumes, and management acknowledged ongoing adoption barriers including catheter supply, GenesisX validation, and X-ray compatibility.
• Management reiterated its expectation of reaching cash-flow profitability in the first half of 2027 without additional financing, assuming continued catheter adoption and modest system sales. The company also highlighted longer-term growth opportunities from a wireless/mobile robot, pulse-field-ablation catheters, AI-enabled surgery, and the recently completed Robocath acquisition.

Stereotaxis Stock Performance

STXS stock traded down $0.06 during mid-day trading on Wednesday, reaching $1.40. The company had a trading volume of 1,372,561 shares, compared to its average volume of 608,693. The firm has a fifty day simple moving average of $1.63 and a 200 day simple moving average of $1.87. The company has a market capitalization of $137.10 million, a price-to-earnings ratio of -5.83 and a beta of 1.37. Stereotaxis has a fifty-two week low of $1.24 and a fifty-two week high of $3.59.

Hedge Funds Weigh In On Stereotaxis

Institutional investors and hedge funds have recently modified their holdings of the company. Geode Capital Management LLC grew its position in shares of Stereotaxis by 0.9% in the 2nd quarter. Geode Capital Management LLC now owns 1,478,201 shares of the company’s stock valued at $3,135,000 after buying an additional 13,891 shares during the last quarter. Rhumbline Advisers grew its holdings in shares of Stereotaxis by 223.7% during the second quarter. Rhumbline Advisers now owns 148,913 shares of the company’s stock worth $316,000 after purchasing an additional 102,916 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Stereotaxis during the second quarter worth about $78,000. Envestnet Asset Management Inc. acquired a new stake in shares of Stereotaxis during the third quarter worth about $413,000. Finally, Vanguard Group Inc. lifted its holdings in shares of Stereotaxis by 4.2% in the 3rd quarter. Vanguard Group Inc. now owns 3,441,091 shares of the company’s stock valued at $10,702,000 after purchasing an additional 138,482 shares during the last quarter. Institutional investors and hedge funds own 45.35% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on STXS. TD Cowen reduced their price target on shares of Stereotaxis from $5.00 to $3.00 and set a “buy” rating on the stock in a research report on Wednesday. Citigroup reiterated a “market outperform” rating on shares of Stereotaxis in a research report on Wednesday, June 3rd. Finally, Piper Sandler reissued an “overweight” rating and set a $3.50 target price (down from $4.00) on shares of Stereotaxis in a research note on Wednesday, May 13th. Five analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $3.70.

Key Headlines Impacting Stereotaxis

Here are the key news stories impacting Stereotaxis this week:

• Positive Sentiment: TD Cowen maintained a Buy rating while lowering its price target from $5.00 to $3.00. The revised target still implies substantial upside from recent trading levels, signaling that the analyst views the selloff as potentially excessive. Benzinga analyst price-target report
• Positive Sentiment: Management expects recurring revenue to reach approximately $8 million in the fourth quarter of 2026. The outlook suggests growing adoption of the company’s MAGiC system, although demand is currently limited by supply constraints. Seeking Alpha recurring-revenue report
• Neutral Sentiment: Stereotaxis reported second-quarter revenue of $7.67 million and an adjusted loss of $0.05 per share. The EPS result matched the consensus estimate cited by MarketBeat, but the company’s broader business update points to a still-developing growth and commercialization story. Stereotaxis second-quarter results
• Negative Sentiment: Revenue fell short of the approximately $8.35 million analyst estimate, while Zacks said the $0.05-per-share loss was worse than its $0.03 expected loss. Stereotaxis also reported a negative net margin of 69.5% and negative return on equity, reinforcing concerns about profitability and execution. Zacks Stereotaxis earnings report

Stereotaxis Company Profile

Stereotaxis, Inc is a medical device company that develops and commercializes robotic magnetic navigation systems for use in electrophysiology procedures. Its core technology leverages precisely controlled magnetic fields to guide ultra-thin, magnetically enabled catheters through the vascular system, allowing physicians to perform complex cardiac ablation and diagnostic procedures with enhanced precision and stability. This platform aims to reduce procedure times and radiation exposure for both patients and clinical staff.

The company’s flagship offering, the Niobe Magnetic Navigation System, integrates with a variety of catheter types and electrophysiology mapping systems to support treatment of arrhythmias such as atrial fibrillation and ventricular tachycardia.